These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 18310826)

  • 21. The future of osteoporosis treatment - a research update.
    Lippuner K
    Swiss Med Wkly; 2012; 142():w13624. PubMed ID: 22815185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strontium ranelate: a physiological approach for an improved bone quality.
    Ammann P
    Bone; 2006 Feb; 38(2 Suppl 1):15-8. PubMed ID: 16455318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro.
    Bonnelye E; Chabadel A; Saltel F; Jurdic P
    Bone; 2008 Jan; 42(1):129-38. PubMed ID: 17945546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Future therapeutic targets in osteoporosis.
    Deal C
    Curr Opin Rheumatol; 2009 Jul; 21(4):380-5. PubMed ID: 19461517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Advances in the field of osteoporosis].
    Vignot E; Delmas PD
    Rev Prat; 2007 Oct; 57(15):1629-31. PubMed ID: 18080418
    [No Abstract]   [Full Text] [Related]  

  • 26. Could strontium ranelate have a synergistic role in the treatment of osteoporosis?
    Blake GM; Compston JE; Fogelman I
    J Bone Miner Res; 2009 Aug; 24(8):1354-7. PubMed ID: 19558313
    [No Abstract]   [Full Text] [Related]  

  • 27. Recent developments in cathepsin K inhibitor design.
    Grabowskal U; Chambers TJ; Shiroo M
    Curr Opin Drug Discov Devel; 2005 Sep; 8(5):619-30. PubMed ID: 16159024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Newly developed drugs to improve bone strength].
    Hagino H
    Clin Calcium; 2016 Jan; 26(1):99-105. PubMed ID: 26728536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone forming agents for the management of osteoporosis.
    Reginster JY; Neuprez A; Beaudart Ch; Buckinx F; Slomian J; Disteche S; Bruyere O
    Panminerva Med; 2014 Jun; 56(2):97-114. PubMed ID: 24642527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Osteoporosis: from cost-effect characteristics to clinical efficacy and safety of strontium ranelate (bivalos)].
    Dydykina IS; Tsurko VV
    Ter Arkh; 2008; 80(5):85-91. PubMed ID: 18590124
    [No Abstract]   [Full Text] [Related]  

  • 31. Improvement in bone strength parameters. The role of strontium ranelate.
    Tournis S
    J Musculoskelet Neuronal Interact; 2007; 7(3):266-7. PubMed ID: 17947810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Monoclonal antibodies to sclerostin for the treatment of osteoporosis].
    Soen S
    Clin Calcium; 2013 Jun; 23(6):884-9. PubMed ID: 23719502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Update and perspectives of anabolic therapies for osteoporosis].
    Endo I; Matsumoto T
    Clin Calcium; 2012 Mar; 22(3):327-33. PubMed ID: 22370299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strontium ranelate: the first agent of a new therapeutic class in osteoporosis.
    Neuprez A; Hiligsmann M; Scholtissen S; Bruyere O; Reginster JY
    Adv Ther; 2008 Dec; 25(12):1235-56. PubMed ID: 19066755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Osteoanabolics and the forthcoming drugs for the treatment of osteoporosis].
    Grazio S
    Reumatizam; 2014; 61(2):95-9. PubMed ID: 25427402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Strontium ranelate: new perspectives for the management of osteoporosis.
    Cortet B
    Rheumatology (Oxford); 2009 Oct; 48 Suppl 4():iv1-2. PubMed ID: 19783588
    [No Abstract]   [Full Text] [Related]  

  • 37. [Strontium ranelate (Osseor)--unique double mechanism--physiologic bone treatment as live tissue].
    Novak S
    Reumatizam; 2007; 54(2):83-4. PubMed ID: 18351151
    [No Abstract]   [Full Text] [Related]  

  • 38. Monoclonal antibodies for the treatment of osteoporosis.
    Lewiecki EM
    Expert Opin Biol Ther; 2013 Feb; 13(2):183-96. PubMed ID: 23253281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cathepsin K inhibitors: a novel target for osteoporosis therapy.
    Stoch SA; Wagner JA
    Clin Pharmacol Ther; 2008 Jan; 83(1):172-6. PubMed ID: 18073778
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cathepsin K inhibitors and antisclerostin antibodies. The next treatments for osteoporosis?
    Chapurlat R
    Joint Bone Spine; 2016 May; 83(3):254-6. PubMed ID: 26919802
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.